OX 401
Alternative Names: OX-401Latest Information Update: 12 Sep 2023
At a glance
- Originator Onxeo SA
- Developer Valerio Therapeutics
- Class Antineoplastics; Immunotherapies; Oligonucleotides
- Mechanism of Action Poly(ADP-ribose) polymerase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 12 Sep 2023 Preclinical development is ongoing in Cancer in France (Parenteral) (Onxeo SA pipeline; September 2023)
- 28 Jul 2023 No recent reports of development identified for preclinical development in Cancer in France (Parenteral)
- 17 Sep 2020 Onxeo plans a clinical trial for cancer in September 2022